Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Aligos Therapeutics (ALGS) Return on Sales (2021 - 2025)

Aligos Therapeutics (ALGS) has disclosed Return on Sales for 5 consecutive years, with 117.64% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Sales fell 14840.0% year-over-year to 117.64%, compared with a TTM value of 11.07% through Dec 2025, down 15734.0%, and an annual FY2025 reading of 11.07%, up 38178.0% over the prior year.
  • Return on Sales was 117.64% for Q4 2025 at Aligos Therapeutics, down from 42.56% in the prior quarter.
  • Across five years, Return on Sales topped out at 138.55% in Q1 2025 and bottomed at 1013.63% in Q3 2024.
  • Average Return on Sales over 5 years is 68.26%, with a median of 11.37% recorded in 2022.
  • The sharpest move saw Return on Sales crashed -100526bps in 2024, then soared 97107bps in 2025.
  • Year by year, Return on Sales stood at 102.76% in 2021, then soared by 98bps to 1.57% in 2022, then tumbled by -364bps to 7.3% in 2023, then surged by 521bps to 30.76% in 2024, then crashed by -482bps to 117.64% in 2025.
  • Business Quant data shows Return on Sales for ALGS at 117.64% in Q4 2025, 42.56% in Q3 2025, and 16.44% in Q2 2025.